Natera, Inc. $NTRA Shares Acquired by Graham Capital Management L.P.

Graham Capital Management L.P. lifted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 729.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 25,747 shares of the medical research company’s stock after purchasing an additional 22,644 shares during the period. Graham Capital Management L.P.’s holdings in Natera were worth $5,898,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Persistent Asset Partners Ltd acquired a new stake in shares of Natera during the fourth quarter worth about $340,000. Polar Capital Holdings Plc acquired a new stake in shares of Natera during the fourth quarter worth about $1,913,000. Rothschild Wealth LLC acquired a new stake in shares of Natera during the fourth quarter worth about $412,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Natera during the fourth quarter worth about $131,000. Finally, Board of Trustees of The Leland Stanford Junior University acquired a new stake in shares of Natera during the fourth quarter worth about $7,171,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Trading Up 1.4%

NASDAQ NTRA opened at $220.11 on Wednesday. The business’s 50 day moving average is $206.92 and its two-hundred day moving average is $215.57. Natera, Inc. has a 12-month low of $131.81 and a 12-month high of $256.36. The stock has a market capitalization of $31.52 billion, a price-to-earnings ratio of -135.04 and a beta of 1.56.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 41,124 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the transaction, the chief executive officer owned 108,743 shares in the company, valued at approximately $24,035,465.29. The trade was a 27.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gail Boxer Marcus sold 11,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $217.21, for a total value of $2,389,310.00. Following the transaction, the director owned 6,183 shares in the company, valued at $1,343,009.43. The trade was a 64.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 159,378 shares of company stock worth $34,640,860 in the last three months. 5.05% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Evercore restated an “outperform” rating and issued a $270.00 price target on shares of Natera in a research report on Friday, May 8th. William Blair assumed coverage on Natera in a research report on Tuesday, April 14th. They issued an “outperform” rating on the stock. Wolfe Research assumed coverage on Natera in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Finally, Royal Bank Of Canada assumed coverage on Natera in a research report on Thursday, June 11th. They issued an “outperform” rating and a $275.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $256.53.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.